Low nitric oxide bioavailability is associated with better responses to sildenafil in patients with erectile dysfunction

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 9, 2013, Pages 805-811

  Muniz, Jaqueline J ^a   Lacchini, Riccardo ^b   Sertório, Jonas T C ^a   Jordão Jr , Alceu A ^b   Nobre, Yuri T D A ^b   Tucci Jr , Silvio ^b   Martins, Antônio C P ^b   Tanus Santos, Jose E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Erectile dysfunction; Nitric oxide; Nitrite; Oxidative stress; Sildenafil

Indexed keywords

ANTIOXIDANT; FERRIC REDUCING ABILITY OF PLASMA; GLUTATHIONE; NITRIC OXIDE; NITRITE; SILDENAFIL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOAVAILABILITY; BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; ERECTILE DYSFUNCTION; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PENIS ERECTION; PROTEIN CARBONYLATION; TREATMENT RESPONSE;

ADULT; AGED; BIOLOGICAL AVAILABILITY; DIABETES MELLITUS, TYPE 2; ERECTILE DYSFUNCTION; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; NITRITES; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROTEIN CARBONYLATION; PURINES; SULFONES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TREATMENT OUTCOME;

EID: 84883212890     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0882-z     Document Type: Article

References (46)

1. Agarwal A, Nandipati KC, Sharma RK, Zippe CD, Raina R (2006) Role of oxidative stress in the pathophysiological mechanism of erectile dysfunction. J Androl 27(3):335-347
2. Angulo J, Gonzalez-Corrochano R, Cuevas P, Fernandez A, La Fuente JM, Rolo F et al (2010) Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries. J Sex Med 7(2 Pt 1):758-768
3. Awad A, Alsaid B, Bessede T, Droupy S, Benoit G (2011) Evolution in the concept of erection anatomy. Surg Radiol Anat 33(4):301-312
4. Benet AE, Melman A (1995) The epidemiology of erectile dysfunction. Urol Clin North Am 22(4):699-709
5. Benzie IF, Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 239(1):70-76
6. Bird RP, Draper HH (1984) Comparative studies on different methods of malonaldehyde determination. Methods Enzymol 105:299-305
7. Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ (2003) Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl 24(6 Suppl):S17-S37
8. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH (1992) Nitric oxide: a physiologic mediator of penile erection. Science 257(5068):401-403
9. Burnett AL, Strong TD, Trock BJ, Jin L, Bivalacqua TJ, Musicki B (2009) Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction. J Urol 181(1):245-251
10. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH (1999) Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 54(2):346-351
11. Carson CC, Lue TF (2005) Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 96(3):257-280
12. Ceron CS, Castro MM, Rizzi E, Montenegro MF, Fontana V, Salgado MC et al (2010) Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 160(1):77-87
13. Corbin JD, Francis SH, Webb DJ (2002) Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 60(2 Suppl 2):4-11
14. de Tejada IS (2004) Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat. Int J Impot Res 16(Suppl 1):S40-S42
15. De Young L, Yu D, Bateman RM, Brock GB (2004) Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction. J Androl 25(5):830-836
16. Dias-Junior CA, Souza-Costa DC, Zerbini T, da Rocha JB, Gerlach RF, Tanus-Santos JE (2005) The effect of sildenafil on pulmonary embolism-induced oxidative stress and pulmonary hypertension. Anesth Analg 101(1):115-120
17. Dias-Junior CA, Neto-Neves EM, Montenegro MF, Tanus-Santos JE (2010) Hemodynamic effects of inducible nitric oxide synthase inhibition combined with sildenafil during acute pulmonary embolism. Nitric Oxide 23(4):284-288
18. Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K et al (2010) Pharmacotherapy for erectile dysfunction. J Sex Med 7(1 Pt 2):524-540
19. Forstermann U (2010) Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 459(6):923-939
20. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (1998) Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 338(20):1397-1404
21. Guay AT (2001) Sexual dysfunction in the diabetic patient. Int J Impot Res 13(Suppl 5):S47-S50
22. Hu ML (1994) Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 233:380-385
23. Jensen J, Lendorf A, Stimpel H, Frost J, Ibsen H, Rosenkilde P (1999) The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens 12(3):271-275
24. Jones RW, Rees RW, Minhas S, Ralph D, Persad RA, Jeremy JY (2002) Oxygen free radicals and the penis. Expert Opin Pharmacother 3(7):889-897
25. Kelm M, Preik-Steinhoff H, Preik M, Strauer BE (1999) Serum nitrite sensitively reflects endothelial NO formation in human forearm vasculature: evidence for biochemical assessment of the endothelial l-arginine-NO pathway. Cardiovasc Res 41(3):765-772
26. Kleinbongard P, Dejam A, Lauer T, Rassaf T, Schindler A, Picker O et al (2003) Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 35(7):790-796
27. Lacchini R, Silva PS, Tanus-Santos JE (2010) A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins. Basic Clin Pharmacol Toxicol 106(5):357-361
28. Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Feelisch M et al (2001) Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci U S A 98(22):12814-12819
29. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG et al (1990) Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186:464-478
30. Martinez ML, Rizzi E, Castro MM, Fernandes K, Bendhack LM, Gerlach RF et al (2008) Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. Eur J Pharmacol 599(1-3):110-116
31. McVary KT (2007) Clinical practice. Erectile dysfunctionh. N Engl J Med 357(24):2472-2481
32. Metzger IF, Souza-Costa DC, Marroni AS, Nagassaki S, Desta Z, Flockhart DA et al (2005) Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genomics 15(8):565-570
33. Metzger IF, Sertorio JT, Tanus-Santos JE (2006) Relationship between systemic nitric oxide metabolites and cyclic GMP in healthy male volunteers. Acta Physiol (Oxf) 188(2):123-127
34. Metzger IF, Sertorio JT, Tanus-Santos JE (2007) Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. Free Radic Biol Med 43(6):987-992
35. Metzger IF, Ishizawa MH, Rios-Santos F, Carvalho WA, Tanus-Santos JE (2011) Endothelial nitric oxide synthase gene haplotypes affect nitrite levels in black subjects. Pharmacogenomics J 11(6):393-399
36. Muniz JJ, Lacchini R, Rinaldi TO, Nobre YT, Cologna AJ, Martins AC et al (2013) Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction. Pharmacogenomics J 13(2):189-196
37. Nagassaki S, Sertorio JT, Metzger IF, Bem AF, Rocha JB, Tanus-Santos JE (2006) eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic Biol Med 41(7):1044-1049
38. Nagassaki S, Herculano RD, Graeff CF, Tanus-Santos JE (2009) eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity. Eur J Clin Pharmacol 65(4):385-392
39. Neto-Neves EM, Dias-Junior CA, Uzuelli JA, Pereira RP, Spiller F, Czaikoski PG et al (2011) Sildenafil improves the beneficial hemodynamic effects exerted by atorvastatin during acute pulmonary thromboembolism. Eur J Pharmacol 670(2-3):554-560
40. Padma-Nathan H, Steers WD, Wicker PA (1998) Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group. Int J Clin Pract 52(6):375-379
41. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49(6):822-830
42. Sandner P, Hutter J, Tinel H, Ziegelbauer K, Bischoff E (2007) PDE5 inhibitors beyond erectile dysfunction. Int J Impot Res 19(6):533-543
43. Schwartz BG, Kloner RA (2009) How to save a life during a clinic visit for erectile dysfunction by modifying cardiovascular risk factors. Int J Impot Res 21(6):327-335
44. Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ (2011) Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. J Diabetes Complications 25(2):129-136
45. Toda N, Ayajiki K, Okamura T (2005) Nitric oxide and penile erectile function. Pharmacol Ther 106(2):233-266
46. Vicari E, La Vignera S, Condorelli R, Calogero AE (2009) Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process. J Sex Med 7(3):1247-1253